Stock Report

All about this stock under one free report Last Updated: 26-Oct-2026

Stock Rating

Is this stock worth it? Our ratings reveal the truth.

Wealth Insight New Issue

This month’s issue could change how you invest, read now.

Recently Viewed

Neuland Lab Peer Comparison

Stock Card factsheet watchlist-stock-modal share-fund-plan-icon

NSE: NEULANDLAB | BSE: 524558

₹18,865.00

up-down-arrow ₹-70.00 (-0.37%)

As on 23-Oct-2026IST

Market cap

info icon

₹24,280 Cr

Revenue (TTM)

info icon

₹2,372 Cr

P/E Ratio

info icon

48.8

P/B Ratio

info icon

12

Div. Yield

info icon

0.2 %

Edit peer-selector-edit
Neuland Lab Emcure Pharmaceuticals Alivus Life Sciences Concord Biotech Sudeep Pharma
Market cap (₹ Cr)
 24,280 33,547 15,313 12,856 10,890
Revenue (₹ Cr)
 2,372 9,683 2,590 1,108 676
Net Profit (₹ Cr)
 497.77 1,018.97 603.02 270.18 183.60
Net Margin (%)
 20.72 10.47 22.63 23.29 26.06
RoE (%)
 28.49 21.30 19.61 14.45 22.72
Price to Earnings
 48.78 33.17 25.39 46.68 59.63
Price-To-Book
 12.01 6.41 4.39 6.20 11.79

Income Statement (₹ Cr)

Neuland Lab Emcure Pharmaceuticals Alivus Life Sciences Concord Biotech Sudeep Pharma
Operating Revenue arrow
2,371.81 9,683.45 2,590.40 1,108.39 675.61
Total Income arrow
2,402.61 9,730.84 2,664.23 1,159.90 704.48
Total Expenditure arrow
1,608.91 7,739.53 1,753.71 720.01 442.67
EBITDA arrow
762.90 1,943.92 836.69 388.38 232.94
Depreciation arrow
98.11 425.10 78.88 74.78 15.56
EBIT arrow
664.79 1,518.82 757.81 313.60 217.38
Interest arrow
26.33 148.45 5.43 0.26 7.96
Other Income arrow
30.80 47.39 73.83 51.50 28.87
Exceptional Items arrow
0.00 -27.85 -25.66 -3.28 0.00
Profit before Tax arrow
669.26 1,389.91 800.55 361.56 238.30
Provision for Tax arrow
171.48 370.94 197.53 91.39 54.69
Profit after Tax arrow
497.77 1,018.97 603.02 270.18 183.60

Liabilities (₹ Cr)

Neuland Lab Emcure Pharmaceuticals Alivus Life Sciences Concord Biotech Sudeep Pharma
Shareholder's Funds arrow
1,874.47 4,950.03 3,332.13 2,017.06 883.34
Minority Interest arrow
0.00 -7.58 0.00 2.51 -0.97
Non-Current Liabilities arrow
345.47 723.57 142.73 50.51 74.82
Current Liabilities arrow
710.20 3,912.24 508.04 169.08 201.96
Total Liabilities arrow
2,930.14 9,514.48 4,157.10 2,231.79 1,174.38

Assets (₹ Cr)

Neuland Lab Emcure Pharmaceuticals Alivus Life Sciences Concord Biotech Sudeep Pharma
Non-Current Assets arrow
1,290.62 3,392.16 1,321.38 957.22 477.92
Current Assets arrow
1,483.13 5,612.10 2,649.36 1,250.11 623.97
Total Assets arrow
2,930.14 9,514.48 4,157.10 2,231.79 1,174.38
Total Debt* arrow
196.61 1,204.08 0.00 0.00 148.29
Net Current Assets arrow
772.93 1,699.86 2,141.33 1,081.04 422.01
Contingent Liabilities arrow
13.18 258.92 4.82 3.76 --

Cashflow (₹ Cr)

Neuland Lab Emcure Pharmaceuticals Alivus Life Sciences Concord Biotech Sudeep Pharma
Cash From Operating Activities arrow
346.68 943.55 565.41 266.88 69.55
Cash Flow from Investing Activities arrow
-423.73 -1,193.06 -570.15 -142.72 -330.93
Cash from Financing Activities arrow
20.98 343.43 -64.34 -112.88 247.29
Net Cash Inflow / Outflow arrow
-56.08 93.92 -69.08 11.28 -14.09

Ratios

Profitability Ratios

 Neuland Lab Emcure Pharmaceuticals Alivus Life Sciences Concord Biotech Sudeep Pharma
ROCE (%) arrow
27.50 25.25 24.61 18.04 28.50
ROE (%) arrow
28.49 21.30 19.61 14.45 22.72
ROA (%) arrow
19.48 11.42 16.31 12.66 31.25
EBIT Margin (%) arrow
28.03 15.68 29.25 28.29 32.18
Net Margin (%) arrow
20.72 10.47 22.63 23.29 26.06
Cash Profit Margin (%) arrow
0.00 0.00 0.00 0.00 0.00

Growth Ratios

 Neuland Lab Emcure Pharmaceuticals Alivus Life Sciences Concord Biotech Sudeep Pharma
Revenue Growth (%) arrow
78.33 18.36 7.93 -6.72 23.56
EBIT Growth (%) arrow
303.07 30.43 19.88 -26.64 12.00
Net Profit Growth (%) arrow
182.61 32.39 21.66 -24.38 20.07
EPS Growth (%) arrow
277.72 36.68 25.42 -21.99 50.65
Book Value Growth (%) arrow
22.95 11.36 18.43 11.27 79.97

Valuation Ratios

 Neuland Lab Emcure Pharmaceuticals Alivus Life Sciences Concord Biotech Sudeep Pharma
Price / Earnings arrow
48.78 32.49 24.59 46.28 57.31
Price / Book Value arrow
12.01 6.41 4.39 6.20 11.79
Dividend Yield (%) arrow
0.18 0.20 0.40 0.61 0.16
EV/EBITDA arrow
31.62 17.80 17.37 32.03 46.89
Market Cap (₹ Cr) arrow
15,412.11 30,257.56 11,956.86 10,627.92 6,690.53

Solvency Ratios

 Neuland Lab Emcure Pharmaceuticals Alivus Life Sciences Concord Biotech Sudeep Pharma
Debt to Equity arrow
0.09 0.05 0.00 0.00 0.04
Short term debt to equity ratio arrow
-- 0.16 -- -- 0.12
Current Ratio arrow
2.09 1.43 5.21 7.39 3.09
Quick Ratio arrow
1.37 0.82 3.85 5.46 2.02
Interest Coverage arrow
26.41 10.36 148.49 1,386.30 30.94

Operating Efficiency Ratios

 Neuland Lab Emcure Pharmaceuticals Alivus Life Sciences Concord Biotech Sudeep Pharma
Debtors to sales (%) arrow
22.82 26.46 41.42 41.52 33.68
Asset Turnover arrow
0.93 1.09 0.70 0.52 1.15
Receivable days arrow
77.32 88.68 144.58 169.86 115.16
Inventory Days arrow
80.83 84.11 96.67 97.92 96.15
Payable days arrow
125.94 176.65 135.45 159.68 106.08
Cash Conversion Cycle arrow
32.22 -3.86 105.80 108.11 105.23
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...
loading...